CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that management will be participating in the upcoming investor conferences: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Fireside Chat Time: 1:10 p.m. ETLocation: Boston, MA Leerink Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 8:40 a ...

Core Viewpoint - Intellia Therapeutics, Inc. is set to host a conference call on February 26, 2026, to discuss its fourth quarter and full-year 2025 financial results and business updates [1]. Group 1: Company Overview - Intellia Therapeutics is a leading clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine [3]. - The company aims to develop novel, first-in-class medicines that address significant unmet medical needs and advance treatment paradigms for patients [3]. - Intellia is expanding its CRISPR-based platform with novel editing and delivery technologies to harness the full potential of gene editing [3]. Group 2: Conference Call Details - The conference call will take place at 8 a.m. ET on February 26, 2026 [1]. - U.S. callers can join the teleconference by dialing 1-833-316-0545, while international callers should dial 1-412-317-5726 [2]. - A replay of the call will be available for approximately 90 days on the Events page of Intellia's website [2].

Core Viewpoint - Vertex Pharmaceuticals has demonstrated its ability to develop successful drugs and generate earnings growth, positioning itself as a strong investment opportunity regardless of market conditions [1][2]. Company Overview - Vertex is the global leader in cystic fibrosis (CF) treatment and has expanded into gene editing for blood disorders and pain management, which supports sustained earnings growth [2][5]. - The company produces CFTR modulators that address approximately 90% of genetic mutations associated with CF, significantly improving the quality of life for patients [5][6]. Financial Performance - Vertex expects its non-CF products, including the gene editing treatment Casgevy and pain drug Journavx, to contribute over $500 million to revenue this year [7]. - The total revenue guidance for Vertex for the year is projected to reach as high as $13.1 billion [7]. Investment Strategy - Vertex is characterized as a "compounder," indicating its potential for long-term value appreciation, making it a suitable addition to a diversified investment portfolio [4]. - The company's strong intellectual property portfolio is expected to support its leadership in CF treatment for the coming decade, providing stability and growth for investors [6].

Core Insights - CRISPR Therapeutics AG has shown strong proof of concept as it enters 2026, indicating potential growth and innovation in its offerings [1] - The fiscal year 2025 has demonstrated early-stage commercial traction for the company, suggesting a positive trend in its business operations [1] Financial Performance - The financials of CRISPR Therapeutics AG indicate a stable trading pattern, remaining approximately flat since the last analysis [1] - Despite early commercial traction, the financial details of the company are noted to be under scrutiny, implying a need for careful evaluation of its financial health [1]

Core Insights - 2026 is anticipated to be a significant year for CRISPR Therapeutics, with potential growth opportunities in the biotech sector [1][2] Company Overview - CRISPR Therapeutics is a leader in gene editing, utilizing a CRISPR-based technique to treat diseases by modifying specific genes [4] - The company has achieved regulatory approval for its first CRISPR-based product, Casgevy, which treats blood disorders such as sickle cell disease and beta thalassemia [5] Revenue Potential - The launch of Casgevy is gaining momentum, with the product having "multi-billion-dollar potential," despite the company sharing profits with partner Vertex Pharmaceuticals [6] - The gene editing treatment process is lengthy, which may delay revenue generation, but the long-term prospects are promising [6] Upcoming Catalysts - In 2026, CRISPR Therapeutics plans to release clinical trial updates for several candidates, including CTX310 and CTX611, as well as initiate trials for new candidates targeting refractory hypertension and alpha-1 antitrypsin deficiency [8] - These updates and milestones could positively impact the stock in the near term and contribute to long-term success [9]

Core Viewpoint - Precision BioSciences, Inc. has received a Study May Proceed notification from the U.S. FDA, enabling the company to start clinical trial activities for its FUNCTION-DMD Phase 1/2 trial [1] Group 1 - The company specializes in gene editing using its proprietary ARCUS® platform to develop therapies for diseases with high unmet needs [1] - The FDA's notification allows Precision BioSciences to initiate Institutional Review Board (IRB) activities and activate clinical trial sites [1]

Core Viewpoint - CRISPR Therapeutics is identified as a stock that has the potential to double by 2030, with analysts maintaining positive ratings despite some adjustments in price targets [1][2]. Group 1: Analyst Ratings and Price Targets - Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from $86 to $80, citing an undervalued pipeline and potential late-stage development for up to seven opportunities in 2027 [1]. - Bank of America analyst Alec Stranahan reduced the price target for CRISPR Therapeutics from $93 to $90 while maintaining a Buy rating, reflecting adjustments across its US Biopharmaceuticals coverage [2]. Group 2: Market Context and Trends - Various factors are aligning positively for the biotech sector, including rewards for positive data, large-cap biopharma investing in M&A and licensing, an increasing backlog of private companies, better access to capital, and minimal effects from drug price regulation [4]. - The firm suggests that while biotech has returned, the primary uncertainty lies in the longevity of this trend [4]. Group 3: Company Overview - CRISPR Therapeutics is a gene editing company that develops gene-based medicines for serious human diseases using its CRISPR/Cas9 platform [5].

Core Insights - Beam Therapeutics is focused on gene-editing medicines and has recently seen a significant insider transaction involving the sale of shares by a senior executive [1][5]. Transaction Summary - On January 22, 2026, Bethany J. Cavanagh, Senior Vice President, sold 6,198 shares for approximately $216,933, which represented 15.11% of her direct holdings at that time [1][2][7]. - Post-transaction, Cavanagh holds 34,813 shares valued at around $1,192,693.38 based on the closing price of $34.26 on the trade date [2][7]. Company Overview - Beam Therapeutics reported a total revenue of $55.70 million and a net income of -$414.64 million for the trailing twelve months (TTM) [3]. - The company has 510 employees and experienced a 6.6% price change over the past year as of January 31, 2026 [3]. Company Snapshot - Beam Therapeutics specializes in the research, development, and commercialization of gene editing therapies, targeting conditions such as leukemia and sickle cell disease [4]. Strategic Priorities - The company announced its strategic priorities for 2026, which include advancing genetic medicines and moving products from clinical trials to distribution [5]. - The FDA has shown alignment with one of its leading medicine candidates, and the company aims to advance more solutions through clinical trials for approval by the end of the year [5]. Financial Outlook - Beam Therapeutics expects to have sufficient cash runway to operate until 2029, supported by existing reserves [6]. - The stock increased approximately 11% in 2025, with minimal price change noted as January 2026 concluded [8].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Insights - Ark Invest, led by Cathie Wood, is focusing on innovation themes such as autonomy, gene editing, and advanced air mobility, adding companies like Archer Aviation, Joby Aviation, and Deere and Company to its portfolio [1] - Wood sold approximately 58,000 shares of Palantir Technologies, which represents less than 15% of her total stake, indicating profit-taking and rebalancing rather than a negative outlook on the company [2] - Analysts, including Dan Ives from Wedbush and Tyler Radke from Citigroup, have positive projections for Palantir, with Ives suggesting it could become a trillion-dollar company and Radke upgrading the stock to "Buy" with a price target increase from $210 to $235 [2][3] Company Performance - Palantir Technologies has diversified its revenue sources, with nearly half coming from the commercial segment, reducing its reliance on government contracts [4] - The stock has experienced a significant gain of about 159% over the past year, although it had a remarkable 340% gain in 2024, making it the best performer in the S&P 500 [5] - Currently, Palantir's stock is trading at a forward price-to-earnings (P/E) ratio of 225, which is considerably higher than its five-year average, suggesting that much of the positive outlook is already priced in [6]